At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Azacitidinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction Chemotherapy
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Oct 13, 2006·Updated Aug 22, 2014
In Brief
A Phase 2 clinical trial evaluating Azacitidine for Leukemia. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
The purpose of this study is to find out if patients older than 60, with acute myeloid leukemia, who are in complete remission following initial chemotherapy, will live longer and have a lower rate of leukemia relapse when treated with azacitidine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsCelgene Corporation
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedOct 2006
Primary CompletionOct 2013
Study CompletionAug 2014
TodayJul 2026
First PostedOct 13, 2006
Enrollment StartAug 1, 2006
Primary CompletionOct 1, 2013
Study CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 19.7 years ago
Interventions
Azacitidinedrug
Azacitidine given subcutaneously as outlined in treatment arm.